Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Open Access
- 12 February 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (3), 295-309
- https://doi.org/10.1016/s1470-2045(18)30079-2
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysisBMJ, 2012
- Improper analysis of trials randomised using stratified blocks or minimisationStatistics in Medicine, 2011
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–Results from two randomised studiesEuropean Journal of Cancer, 2010
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancerGynecologic Oncology, 2006
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trialBritish Journal of Cancer, 2006
- Outcome of High-Risk Stage IC, Grade 3, Compared With Stage I Endometrial Carcinoma Patients: The Postoperative Radiation Therapy in Endometrial Carcinoma TrialJournal of Clinical Oncology, 2004
- Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapyGynecologic Oncology, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976